Protease inhibitors for preventing complications associated with ERCP: An updated meta-analysis

Gastrointestinal Endoscopy

Volumn 73, Issue 4, 2011, Pages 700-706.e2

  Seta, Takeshi ^a   Noguchi, Yoshinori ^b  

^a JAPANESE RED CROSS WAKAYAMA MEDICAL CENTER   (Japan)

^b NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

Author keywords

CI; confidence interval; D L; DerSimonian Laird; M H; Mantel Haenszel; NNT; number needed to treat; randomized, controlled trial; RCT; RD; risk difference

Indexed keywords

APROTININ; GABEXATE MESILATE; NAFAMSTAT MESILATE; PLACEBO; ULINASTATIN;

ABDOMINAL PAIN; ARTICLE; DEATH; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; HYPERAMYLASEMIA; MAJOR CLINICAL STUDY; META ANALYSIS; OUTCOME ASSESSMENT; PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SENSITIVITY ANALYSIS;

EID: 79953238453     PISSN: 00165107     EISSN: 10976779     Source Type: Journal    
DOI: 10.1016/j.gie.2010.09.022     Document Type: Article

References (47)

1. A. Andriulli, R. Clemente, and L. Solmi Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial Gastrointest Endosc 56 2002 488 495
2. G. Cavallini, A. Tittobello, and L. Frulloni Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography Gabexate in digestive endoscopy-Italian Group N Engl J Med 335 1996 919 923 (Pubitemid 26314444)
3. T. Tsujino, Y. Komatsu, and H. Isayama Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial Clin Gastroenterol Hepatol 3 2005 376 383 (Pubitemid 40488346)
4. J.W. Yoo, J.K. Ryu, and S.H. Lee Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a prospective, randomized, placebo-controlled trial Pancreas 37 2008 366 370
5. A. Andriulli, G. Leandro, and G. Niro Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis Gastrointest Endosc 51 2000 1 7 (Pubitemid 30051601)
6. A. Andriulli, G. Leandro, and T. Federici Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis Gastrointest Endosc 65 2007 624 632 (Pubitemid 46442832)
7. M. Zheng, Y. Chen, and X. Yang Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials BMC Gastroenterol 7 2007 6 14
8. S. Chen, H. Shi, and X. Zou Role of ulinastatin in preventing post-Endoscopic retrograde cholangiopancreatography pancreatitis Pancreas 2010 Jun 5 [Epub ahead of print]
9. A.R. Jadad, R.A. Moore, and D. Carroll Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12 (Pubitemid 26120810)
10. S. Greenland, and J.M. Robins Estimation of a common effect parameter from sparse follow-up data Biometrics 41 1985 55 68
11. J.P. Higgins, S.G. Thompson, and J.J. Deeks Measuring inconsistency in meta-analysis BMJ 327 2003 557 560
12. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188 (Pubitemid 17189972)
13. R.J. Light, and D.B. Pilemer Summing up: the science of reviewing research 1984 Harvard University Press Cambridge (Mass)
14. C.B. Begg, and M. Mazumdar Operating characteristics of a rank correlation test for publication bias Biometrics 50 1994 1088 1101
15. M. Egger, G. Davey Smith, and M. Schneider Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634 (Pubitemid 27387172)
16. R. Brust, A.B. Thomson, and R.H. Wensel Pancreatic injury following ERCP Failure of prophylactic benefit of Trasylol Gastrointest Endosc 24 1977 77 79 (Pubitemid 8263122)
17. K. Hajiro, D. Tsujimura, and R. Inoue Effect of FOY on hyperamylasemia after endoscopic retrograde cholangiopancreatography Gendai Iryo 10 1978 1375 1379
18. N. Kuno, T. Kasugai, and T. Oguri Study on prevention of complication associated with endoscopic retrograde cholangiopancreatography ERCP): a controlled trial of a new protease inhibitor, FOY, in hyperamylasemia following endoscopic retrograde cholangiopancreatography Gendai Iryo 10 1978 571 575
19. Y. Shimizu, H. Takahashi, and M. Deura Prophylactic effects of preoperative administration of Gabexate Mesilate (FOY) on post-ERCP pancreatitis Gendai Iryo 11 1979 540 544
20. L. Benini, G. Angelini, and E. Lavarini Effect of a new enzyme inhibitor (Gabexate Mesilate- FOY) on hyperenzymemia induced by ERCP A double blind study [abstract] Digestion 32 1985 A165
21. A. Andriulli, L. Solmi, and S. Loperfido Prophylaxis of ERCP- related pancreatitis; a randomized, controlled trial of somatostatin and gabexate mesilate Clin Gastroenterol Hepatol 2 2004 713 718 (Pubitemid 39013432)
22. G.S. Xiong, S.M. Wu, and X.W. Zhang Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis Braz J Med Biol Res 39 2006 85 90
23. S. Benvenuti, L. Zancanella, and L. Piazzi Prevention of post-ERCP pancreatitis with somatostatin versus gabexate mesilate: a randomized placebo-controlled multicenter study Dig Liv Dis 38 2006 S15
24. G. Manes, S. Ardizzone, and G. Lombardi Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study Gastrointest Endosc 65 2007 982 987 (Pubitemid 46783824)
25. C.W. Choi, D.H. Kang, and G.H. Kim Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis Gastrointest Endosc 69 2009 e11 e18
26. T. Ueki, K. Otani, and K. Kawamoto Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial J Gastroenterol 42 2007 161 167 (Pubitemid 46404221)
27. H. Fujishiro, K. Adachi, and T. Imaoka Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study J Gastroenterol Hepatol 21 2006 1065 1069 (Pubitemid 43823296)
28. E. Masci, G. Cavallini, and A. Mariani Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis Am J Gastroenterol 98 2003 2182 2186 (Pubitemid 37305356)
29. F. Tympner, and W. Rsch Effect of secretin and gabexate-mesilate (synthetic protease inhibitor) on serum amylase level after ERCP Z Gastroenterol 20 1982 688 693
30. J. Baillie Increased serum trypsinogen 2 and trypsin 2-1 antitrypsin complex values identify endoscopic retrograde cholangiopancreatography (ERCP)-induced pancreatitis with high accuracy Gastrointest Endosc 47 1998 554 555
31. R. Pezzilli, A. Gabbrielli, and A.M. Labate Does gabexate mesilate affect serum concentrations of acute phase proteins after endoscopic retrograde cholangiopancreatography examination? Hepatogastroenterology 50 2003 851 855 (Pubitemid 36613423)
32. D. Rudin, A. Kiss, and R.V. Wetz Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials J Gastroenterol Hepatol 22 2007 977 983 (Pubitemid 47019864)
33. M.W. Bchler, B. Gloor, and C.A. Muller Acute necrotizing pancreatitis: treatment strategy according to the status of infection Ann Surg 232 2000 619 626
34. E. Masci, and A. Mariani Short-term prophylactic prevention of post-ERCP pancreatitis Gastrointest Endosc 58 2003 816 (Pubitemid 37370512)
35. K. Uemura, Y. Murakami, and Y. Hayashidani Randomized clinical trial to assess the efficacy of ulinastatin for postoperative pancreatitis following pancreaticoduodenectomy J Surg Oncol 98 2008 309 313
36. V. Salamon, H.D. Kuntz, and B. May Wirkung des synthetischen proteinase-inhibitors FOY auf die hyperamylasamie nach ERP K.H. Grozinger, A. Schrey, R.W. Wabnitz, Proteinase-inhibition, FOY workshop, 1981 1982 Wolf G&Sohn Dusseldorf, Germany 132 135
37. P. Gong, Z.Y. Wang, and P.J. Tai Prevention and treatment for post ERCP pancreatitis J Hepatobiliary Surg 12 2004 101 103
38. A.L. Song, L.N. Yin, and Z.M. Kou Prevention effects of ulinastatin on post ERCP hyperamylasemia and acute pancreatitis J Lanzhou Univ (Med Sci) 31 2005 24 25
39. X.T. Chen, Z.Y. Fei, and Y.F. Shen Clinical observation on ulinastatin for the prevention of post-ERCP pancreatitis Shandong Med J 45 2005 44 45
40. M. Iwaki, Y. Ino, and A. Motoyoshi Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats Jpn J Pharmacol 41 1986 155 162 (Pubitemid 16078701)
41. M.L. Freeman, D.B. Nelson, and S. Sherman Complications of endoscopic biliary sphincterotomy N Engl J Med 335 1996 909 918 (Pubitemid 26314443)
42. S. Loperfido, G. Angelini, and G. Benedetti Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study Gastrointest Endosc 48 1998 1 10 (Pubitemid 28337421)
43. E. Masci, G. Toti, and A. Mariani Complications of diagnostic and therapeutic ERCP: a prospective multicenter study Am J Gastroenterol 96 2001 417 423
44. M.L. Freeman, J.A. DiSario, and D.B. Nelson Risk factors for post-ERCP pancreatitis: a prospective, multicenter study Gastrointest Endosc 54 2001 425 434 (Pubitemid 33661145)
45. A. Andriulli, S. Loperfido, and G. Napolitano Incidence rates of post-ERCP complications: a systematic survey of prospective studies Am J Gastroenterol 102 2007 1781 1788 (Pubitemid 47206695)
46. J.H. Ranson, K.M. Rifkind, and D.F. Roses Prognostic signs and the role of operative management in acute pancreatitis Surg Gynecol Obstet 139 1974 69 81
47. W.A. Knaus, E.A. Draper, and D.P. Wagner APACHE: a severity of disease classification system Crit Care Med 13 1985 818 829 (Pubitemid 15250137)